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International donors financing the delivery of antiretroviral treatment (ART) in developing 
countries have recently emphasized their commitment to rigorous evaluation of ART impact on 
population health.  In the same time frame but different contexts, they have announced that they 
will shift funding from vertically-structured (i.e., disease-specific) interventions to horizontally-
structured interventions (i.e., staff, systems and infrastructure that can deliver care for many 
diseases). We analyze likely effects of the latter shift on the feasibility of impact evaluation. 
Methods 
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 We examine the effect of the shift in intervention strategy on (i) outcome measurement, (ii) cost 
measurement, (iii) study-design options, and the (iv) technical and (v) political feasibility of 
program evaluation. 
Results 
As intervention structure changes from vertical to horizontal, outcome and cost measurement are 
likely to become more difficult (because the number of relevant outcomes and costs increases 
and the sources holding data on these measures become more diverse); study design options 
become more limited (because it is often impossible to identify a rigorously defined 
counterfactual in horizontal interventions); the technical feasibility of interventions is reduced 
(because lag times between intervention and impact increase in length and effect mediating and 
modifying factors increase in number); and political feasibility of evaluation is decreased 
(because national policymakers may be reluctant to support the evaluation).  
Conclusions 
In the choice of intervention strategy, policymakers need to consider the effect of intervention 
strategy on impact evaluation. Methodological studies are needed to identify the best approaches 










  Many recent donor initiatives in global health have been vertically structured, but 
prominent donors have announced that they will increasingly fund horizontal 
interventions. 
  At the same time, donors have recently declared that they are committed to rigorous 
evaluations of the impact of their investments on population health. 
  The shift towards more horizontally structured interventions, however, will increase the 
difficulty in conducting impact evaluation. 
  The shift will likely lead to additional problems in measuring exposure, costs and 




The last decade has seen a dramatic scale-up in the delivery of antiretroviral treatment (ART) to 
HIV-infected people in sub-Saharan Africa (SSA). At the end of 2009, almost four million 
people in the region were receiving ART, while five years earlier the figure was less than one 
million.
1  This achievement is especially notable because it occurred predominantly in countries 
with low income and relatively rudimentary health system infrastructures. Much credit goes to 
international donors that provided massive financial and programmatic support.  Many of the 
donor initiatives, such as the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and 
the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) have been vertically-
structured,
2-4 i.e., they are focused on treating HIV infection and its accompanying diseases.  The 
disease specificity of these programs has usually implied that they are organized separately from 
the general health system, employing their own front-line health and management staff, 
delivering treatment in their own facilities, operating their own supply chains, and using their 
own monitoring and evaluation (M&E) systems. 
While the scale-up of ART delivery in SSA is an extraordinary achievement, the number of 
people now receiving ART constitute only about 40% of those who need ART based on WHO 
treatment eligibility criteria.
1  At roughly the same time as the United Nations (UN) has called on 
member states to work towards achieving universal ART coverage by 2015,
5 international 
donors have announced two major shifts in their involvement in ART delivery.  First, several 
prominent donors have announced that they will increasingly fund horizontal interventions,
6 i.e., 
shifting resources from vertical programs into staff, systems, and infrastructure that can deliver 
care for many diseases.  Reasons for this shift include the belief that ART could be delivered 
more efficiently in the general health system if the system’s capacity were improved; a 
recognition that HIV patients commonly suffer from other diseases that are usually treated in the 
general health care system; and worries that vertical interventions for some priority diseases 
divert human and financial resources away from the treatment of other diseases that are also 
major causes of death and disability in developing countries.
7  
The second shift involves key donors declaring a commitment to rigorous scientific evaluations 
of the impact of their investments on population health
8 – a shift from assessing programs in 
terms of process and output indicators such as the number of people treated, to making 
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 assessments based on outcome indicators such as life expectancy among HIV-infected 
individuals.  Reasons for this second shift include the recognition that large investments in health 
interventions need to be justified by demonstrable improvements in population health and that 
“well-designed and empirically grounded research and evaluation of PEPFAR should promote 
improved performance, accountability, informed decision-making, and lessons from 
experience.”
9  
Below, we describe the two shifts in more detail.  We then analyze the likely effects of the first 
shift (from more vertically- to more horizontally-structured health interventions) on the second 
shift, in particular, on (i) outcome measurement, (ii) cost measurement, (iii) options for the 
design of impact evaluation studies, and the (iv) technical and (v) political feasibility of program 
evaluation. 
 
Two shifts in the delivery of HIV treatment and care 
From more vertically structured to more horizontally structured HIV treatment and care delivery 
Although PEPFAR and GFATM have achieved their success in bringing HIV treatment and care 
to scale in SSA through vertically structured programs, the two donor organizations have 
recently shifted funding towards more horizontally-structured interventions.  As PEPFAR 
declares, it “has not had a strategic vision or plan to incorporate a health systems lens into its 
programming. In the first phase of PEPFAR [2004-2009], health systems activities were largely 
ad hoc, varied across countries, and did not always factor in an intervention's impact on the 
country's broader health system.”
10  In contrast, in the current phase [2010-2014], PEPFAR 
“emphasizes the incorporation of health systems strengthening goals into its prevention, care and 
treatment portfolios.”
11  For instance, PEPFAR has committed to train 140,000 “health care 
workers, managers, administrators, health economists, and other civil service employees critical 
to all functions of the health system.”
12  Other examples of PEPFAR investment in horizontal 
interventions include improving “the general supply chain, procurement, and forecasting 
systems”, “supervisory and planning skills” of healthcare management staff, and “referral 
systems”.
13   
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 The movement toward horizontal structures is also articulated in the mission of the U.S. Global 
Health Initiative (GHI), the new umbrella organization for U.S. global health engagements, 
which includes “sustainability through health systems strengthening” along with interventions 
for specific diseases as one of its “core objectives”.
7 The GHI also prioritizes not only HIV, 
malaria and tuberculosis interventions but also support for healthcare that is traditionally 
considered to be part of general primary care, such as family planning and reproductive, 
maternal, and child healthcare.
14 
  Similarly, GFATM states that an “effectively performing 
health system is key to improving the population’s health status, providing protection against 
health-related financial risks and enhancing the health sector’s responsiveness to customers’ 
needs”. For its latest funding round, GFATM encourages countries to apply for “cross-cutting 
HSS [health systems strengthening] interventions, which affect more than one of the three 
diseases (HIV, tuberculosis, malaria)” and “may address broader health MDGs [millennium 
development goals], by for example contributing to maternal and child health”.
15  As examples 
of such “cross-cutting” interventions, GFATM lists “upgrading primary health care facilities, 
strengthening planning and policymaking capacity of the Ministry of Health, [and] improving the 




From M&E to impact evaluation 
PEPFAR aims “to help save the lives of those suffering from HIV/AIDS around the world;”
16  
GFATM states that its mission is “[i]nvesting the world’s money to save lives.”
17   Despite these 
declarations, the two organizations did not emphasize evaluations of intervention impact on 
population health outcomes in the first years of their operations.  Rather, they focused primarily 
on process and output indicators. For instance, PEPFAR regularly reported the number of 
persons it “directly supported with life-saving antiretroviral treatment”
18 based on its M&E 
system, which requires recipients to record these numbers and to report them to PEPFAR 
country offices. The US Institute of Medicine’s 2007 report, PEPFAR Implementation: Progress 
and Promise, did not estimate PEPFAR’s effect on population health outcomes, but assessed 
PEPFAR strategy, resources, management, and the “number of people receiving ART 
[antiretroviral treatment] supported by PEPFAR.”
19  
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 At the national level PEPFAR results are still largely assessed in terms of process and output 
indicators. But in the last few years both organizations have attempted to estimate the impact of 
ART in terms of life-years saved at the global level, for example, in the 2009 PEPFAR Report to 
Congress
18 and in the 2010 GFATM report Innovation and Impact.
20  For instance, the GFATM 
estimated that the programs it supported had saved a total of 4.9 million lives through the end of 
2009. Most recently, GFATM has raised the total estimate to 6.5 million lives through the end of 
2010. 
21  The methodology for arriving at these estimates has not been documented extensively, 
but a brief outline of the approach taken appeared in the Global Fund’s 2007 Partners in Impact 
report.
22  For estimates of HIV-related mortality averted through ART, two scenarios are 
compared, one with a survival curve assumed for patients on ART, and the other with an 
“untreated” survival curve of patients needing but not receiving ART. The survival assumptions 
follow those used by UNAIDS in their routine estimates on the global HIV epidemic.
23 In 
addition to the GFATM annual reports, there has also been an impact assessment published as a 
journal article by Komatsu and colleagues.
24 The methods used in the article differed only 
slightly from those used in the official GFATM reports.   
While the causal link between the measured output (individuals receiving ART) and the 
modelled outcome (life-years saved) is relatively direct, these models require a number of 
assumptions that may not hold, leading to biased results.  First, the models assume an ART effect 
on the survival of each patient receiving the treatment, which is derived from a comparison of 
AIDS mortality observed in persons needing but not receiving ART in some cohort studies with 
the mortality among persons needing and receiving ART in other studies.  However, the 
mortality in the cohort studies of persons needing but not receiving ART may not be a good 
counterfactual for the mortality the persons needing and receiving ART would have experienced 
had they not received the treatment.  Access to ART is not equal for all people eligible for ART
25 
and thus actual ART patients are likely to differ from potential patients in many characteristics 
that affect mortality, such as sex, age, income, nutritional status, and retention and adherence 
behaviours.  Second, the models assume that none of the life-years saved with PEPFAR or 
GFATM support would have been realized in the absence of the support.  However, this 
counterfactual assumption will not be met if PEPFAR and GFATM caused changes – either 
increases or decreases – in national spending on ART, which would not have occurred if the 
organizations had not invested in ART.
26-29 Third, the models assume that ART delivery has no 
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 effect on the capacity of the general health system to provide HIV-unrelated health services.  
However, it is plausible that the substantial investment in ART has either positively or negatively 
affected general health systems.
26-31  For instance, ART provision requires human and physical 
resources, which may have been drawn away from the delivery of other health care,
29,32  leading 
to loss of life-years, which would not have occurred without the investment in ART.  On the 
other hand, it is also possible that infrastructure that has been built to provide ART, such as 
supply chains for medicines, has improved the delivery of other health care, and that the HIV-
related initiatives have led to increased political commitment of governments to improve public 
health in general, improving health outcomes of patients who do not suffer from HIV.
29  
For these reasons, existing model-based impact estimates may not reflect the true causal effect of 
PEPFAR and GFATM – a fact that lends support to the need for an increased focus on empirical 
impact evaluations that base causal effect estimation on “a rigorously defined counterfactual to 
control for factors other than the intervention that might account for the observed change”.
8  
The initial shift from output monitoring to mathematical models of intervention impact has now 
been followed by a shift from modeling to measurement of impact in empirical evaluation 
studies with rigorously defined counterfactuals.  This new shift has been attributed to a change in 
the conception of large-scale donor support for ART from an “emergency response” to a 
foundation for long-term provision of the life-saving treatment to millions of people in sub-
Saharan Africa for their entire lives.
6  As Padian and colleagues write:
33  
“In the first phase of PEPFAR, these activities were appropriately carried out in an emergency fashion with 
the goal of using available interventions to reduce mortality and alleviate suffering from HIV disease as 
quickly and effectively as possible. … Commensurate with the emergency response, however, state-of-the-
art monitoring, evaluation, and research methodologies were not fully integrated or systematically 
performed. In the second phase of PEPFAR, characterized by an increased emphasis on sustainability, 
programs must demonstrate value and impact to be prioritized within complex and resource-constrained 
environments. In this context, there is a greater demand to causally attribute outcomes to programs.”  
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 Impact evaluation under alternative intervention strategies  
The shift toward rigorous, empirical evaluations of the impact of PEPFAR and GFATM 
interventions is critical for generating understanding of the true causal effects of the two 
initiatives.   The feasibility of such studies, however, will differ depending on whether the 
intervention is structured vertically or horizontally.  Figure 1 depicts in the abstract how different 
aspects of the shift in intervention structure from vertical to horizontal affect the feasibility of 
impact evaluation; Figure 2 provides an example.  Below, we explain how intervention structure 
affects health outcomes measurement, cost measurement, study design options, and the technical 
and political feasibility of evaluations.  
Health outcomes measurement 
Vertical interventions are intended to affect narrow sets of health outcomes (e.g., mortality and 
morbidity in HIV-infected individuals), while horizontal interventions are by definition intended 
to affect a wide range of health outcomes.  Horizontal interventions that are financed by 
organizations with disease-specific mandates, such as PEPFAR or GFATM, thus raise an issue 
about the outcomes to observe for impact evaluation.  Full evaluation of horizontal interventions 
is more difficult than full evaluation of vertical interventions because wider populations with a 
larger set of morbidities and causes of mortality have to be observed; but narrow evaluation of 
horizontal interventions for only HIV-infected persons is not useful for many decision-making 
purposes because potentially large components of the total effect are neglected. For instance, two 
health worker interventions may have comparable effects on morbidity and mortality in HIV-
infected individuals, but one may save many more life-years in HIV-uninfected populations than 
the other.  We expect policymakers to prefer the intervention that saves more life-years in HIV-
uninfected populations and to thus require a comprehensive evaluation of intervention outcomes.  
Cost measurement 
A further complication in the evaluation of horizontal interventions arises when costs are 
considered in addition to outcomes.  A common metric used to present the impact of the large-
scale global health interventions in recent years has been “value for money”, i.e., the size of a 
benefit or effect per financial investment in an intervention.
34 35 For instance, “[t]he Global Fund 
is committed to measuring and demonstrating the relationship between its financial investments 
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 and their outcomes.  Value for money measurement will also provide countries with tools to 
improve program efficiency, which they can use in resource mobilization.”
35 
A vertical program is commonly financed exclusively by one agency.  Where multiple funders 
contribute to a vertical program, the contributions of the different agencies are often clearly 
visible to all funders.  For instance, in South Africa, the government and PEPFAR both 
contribute to the funding of the public-sector ART program.
36  This joint effort is well 
coordinated and both parties know the types and quantities of the resources the other party 
contributes and can easily obtain information on the financial outlays for these resources.  In 
contrast, in some types of horizontal programs, it may be much more difficult for the primary 
funder to obtain realistic estimates of the financial contributions of other agencies, because these 
programs will likely require more diverse sets of inputs and because these inputs will not be 
utilized exclusively by the horizontal program. For instance, programs improving the supply 
chains of medicines to primary care clinics will likely require support by health workers in 
central pharmacies and by the health workers in the primary care clinics receiving the medicines.  
However, these health workers will only spend some portion of their time supporting the supply 
chain intervention.  This portion is unlikely to be known without additional research effort, such 
as time-motion studies or health worker interviews.  The shift from vertical to horizontal 
interventions is thus likely to imply substantially increased difficulty in measuring an 
intervention’s cost-effectiveness or “value for money”. 
Study designs 
As we note above, the shift to more rigorous evaluations of intervention impact requires studies 
to be based on “a rigorously defined counterfactual”,
8 i.e., a study design that minimizes threats 
to validity in the estimation of the outcome that would have occurred had those who received the 
intervention not received it.  Randomized controlled experiments are often viewed as the gold-
standard of impact evaluation, because the random assignment of individuals or other units of 
observation to an intervention group and to a control group not receiving the intervention ensures 
that the two groups are as similar as possible regarding all relevant factors that can affect the 
outcome, other than the intervention itself. Given sufficiently large samples, randomization will 
adequately control confounding and allow unbiased effect size estimation. Where randomized 
controlled experiments are not possible, observational approaches can be employed to estimate 
10 
 effect size using rigorously defined counterfactuals.
26 These approaches include difference-in-
difference estimation (where the counterfactual is the difference in an outcome before and after 
the time of an intervention in individuals living in communities that did not receive the 
intervention),
37 interrupted time series (where the counterfactual is the evolution of an outcome 
over time before the intervention took place),
38 regression discontinuity (where the 
counterfactual is the outcome in individuals whose score on a certain variable falls below the 
threshold above which individuals receive the intervention),
39 or instrumental-variable 
approaches (where the counterfactual resembles that of a randomized experiment because “the 
forces of nature or government policy” have randomly determined treatment assignment or 
intensity).
40  
In general, vertical interventions are more likely than horizontal interventions to allow 
researchers control over the assignment of individuals or communities to intervention and control 
groups.  For instance, randomized controlled experiments of vertical ART programs would be 
feasible, if researchers could randomize the time when a particular geographically bound 
community or cluster receives an intervention.  An example is stepped-wedge cluster-
randomized experiments
41 where those locations that receive the intervention later serve as 
counterfactuals for those that received them earlier. Stepped implementation of large-scale ART 
programs is common,
36 and it is technically feasible to randomize the implementation scale-up 
across space and time (although this approach has been uncommon, possibly because of political 
resistance to randomization of intervention implementation or simple failure to consider such an 
approach before starting large-scale ART programs).  In contrast, many horizontal interventions 
cannot be randomized because they will always affect the entire health system of a country.  For 
instance, changes in the legislation regulating a country’s health workforce, the establishment of 
national institutions to systematically assess evidence on healthcare interventions, or market 
interventions to reduce drug prices, cannot be randomly assigned to individuals or sub-national 
areas. Such horizontal interventions that function through central mechanisms and affect an 
entire country equally are also difficult to evaluate using observational approaches, because they 
require cross-national data for a rigorous counterfactual.  
 
Horizontal interventions that do not equally affect the entire health system of a country (at least 
not immediately) can theoretically be randomized
42 or evaluated, exploiting “naturally 
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 occurring” differences in intervention expansion over time and across space.
43  However, such 
horizontal interventions will often be difficult to evaluate in practice because neither the 
exposure nor the outcome of interest are easy to assess.  For instance, to evaluate the impact of a 
horizontal program to train health workers in a country, it would be necessary to keep track of all 
health workers trained by the program as they find – and leave – employment in different areas 
of the country and then to establish data collection infrastructures in those areas to measures the 
health outcomes of interest.  By contrast, in the evaluation of vertical interventions, the exposure 
is usually the vertical intervention itself, such as ART delivery, and the outcome can be assessed 
directly through the vertical structures.   
 
In addition, it may be more difficult to identify meaningful observational approaches to 
determine causal relationships for horizontal than for vertical interventions.  For instance, 
discontinuities in treatment assignment, which are necessary for regression discontinuity 
estimation of intervention effects, will often exist for vertical interventions, because treatment 
indicators for particular diseases are commonly determined by applying a fixed threshold to a 
continuously measured biological variable.  A case in point is ART, which is initiated when a 
patient’s CD4 count falls below a certain threshold (e.g., 350 CD4 cells/µl under the latest WHO 
ART treatment guidelines, up from 200 CD4 cells/µl prior to mid-2010).  This discontinuity (and 
changes in this discontinuity) in the relationship between CD4 count and ART allows estimation 
of the effect of ART on outcomes such as mortality, employment, or sexual behaviour, by 
comparing these outcomes in patients with CD4 counts just above and just below the threshold.   
 
It is unlikely that such discontinuous treatment assignment rules can be identified for most 
horizontal interventions, such as health worker training, supply chain improvements, or the 
establishment of new procurement and forecasting systems, because the processes through which 
such interventions are placed and reach patients are influenced by the complex interplay of many 
factors that are poorly understood and cannot be summarized in a simple discontinuity on a 
single variable.  Similarly, it may be more difficult to use instrumental-variable approaches to 
estimate the effectiveness of horizontal as compared to vertical interventions.  One reason for 
this increased difficulty is that horizontal interventions are more likely to consist of multiple 
important components, the presence and intensity of which can vary across interventions.  For 
12 
 instance, an intervention aiming to reduce drug stock-outs in primary care clinics may consist of 
a range of separate components intervening in the forecasting system, the procurement system, 
and the supply chain from a central pharmacy to the clinic. To estimate the overall effectiveness 
of a horizontal intervention, researchers may thus face the difficult task of identifying and 
measuring separate instruments for each intervention component.  Overall, it seems likely that 
the shift from vertical to horizontal intervention strategies will decrease the options for 
evaluation study designs that are appropriate and feasible to examine intervention impact.   
 
Technical feasibility of evaluation 
Another aspect of interventions – the time lag between intervention start and the first possible 
observation of intervention impact on outcomes – both affects the feasibility of evaluation and 
differs between vertical and horizontal interventions.  Vertical interventions will commonly 
generate health impacts more quickly than horizontal ones.  This occurs because horizontal 
interventions to benefit HIV-infected populations generally need to be in place before vertical 
ART delivery can begin.  For instance, many types of health workers, such as doctors and nurses, 
need to be educated and trained for several years before they can deliver ART.  The 
establishment of an electronic patient record system may require procurement of laptops, 
development of software, health worker training, and field testing before it can contribute to the 
quality or efficiency of ART delivery and improve health outcomes in patients. The longer the 
time lags between intervention and outcomes, the more complicated and costly it will be to 
evaluate the intervention.  Evaluation planning will need to precede the implementation of the 
evaluation by longer times and the timing of baseline and post-intervention measurements of 
exposures and outcomes becomes more difficult. 
Even if horizontal interventions can be rigorously evaluated, we may learn less from the 
evaluation results than in the case of the evaluation of vertical interventions, because the 
horizontal interventions are commonly mediated through longer causal chains than vertical ones, 
and the number of factors that can modify intervention effects will likely increase. Take, for 
instance, a training program to increase the capacity of district health managers to plan the 
delivery of health programs.  For this horizontal intervention to have an effect on population 
health, it will be necessary for district health managers to attend the training, successfully acquire 
13 
 new skills in the training, and be willing to use their new skills. The impact on health outcomes 
will then further depend on the capacity of the manager to effect changes in the actual delivery of 
ART.  It is this actual delivery, on the other hand, which is usually the starting point for the 
evaluation of vertical ART programs. Thus, the mediating steps from the district health worker 
intervention to a health impact are many more than those from the ART program to health 
impact, and contextual factors influencing district health managers’ capacity to use newly 
acquired skills will likely increase the heterogeneity of effects across settings. 
Differences in mediating factors will lead to heterogeneity in estimated impacts across settings. 
The larger the number of mediating factors between the intervention and the outcome, the more 
resources will be required to either observe or control for all mediating factors.  As the number 
of mediating factors will commonly increase as the intervention structure changes from vertical 
to horizontal, it is likely that impact evaluation that can shed light on the effects of programs 
across settings or populations will be more complex and require more resources for horizontal 
than for vertical interventions. 
Political feasibility of evaluation 
In addition to the technical feasibility of evaluation, intervention structure is also likely to affect 
the political feasibility of evaluation.  Horizontal interventions, such as improvements in supply 
chains, patient management systems, or health worker training, are likely to take place in close 
interaction with or to be integrated into the general public-sector health system.  Hence, 
researchers will likely need the cooperation of the front-line staff working in the general health 
system to measure exposure and outcomes, or to assess possible mediating factors.  Unlike in 
vertical ART programs, where front-line staff will often be employed or otherwise supported by 
initiatives such as PEPFAR and GFATM, which fund the program, front-line staff in the general 
health system are likely to be public-sector employees. As such, they may be less likely to 
participate in the evaluation of interventions that are funded by initiatives that are not part of the 
public sector.   
Moreover, national and sub-national politicians may be more interested in the evaluation of 
horizontal interventions supporting the general health system than in the evaluation of vertical 
programs, because they are directly responsible for the functioning of the former but not of the 
14 
 latter. This increased interest in the evaluation could imply that they more strongly support the 
evaluation process, because they see the value of the evaluation results for their own work.  
However, it could also imply that they will not be supportive of evaluations by outside agencies, 
because they will not be able to control the dissemination of evaluation results that could be 
embarrassing to them or because they feel that it is their responsibility to initiate and fund 
evaluations of the general health system. Since – unlike in many evaluations of vertical programs 
– the cooperation of policymakers will be needed to conduct evaluation of interventions that are 
related to the general health system, it is possible that such evaluations will not be feasible for 
political reasons, impeding the generation of evidence on their impact. 
Discussion 
We have described possible implications of the shift from vertically- to horizontally-structured 
health interventions for outcome measurement, cost measurement, options for impact evaluation 
study designs, and the technical and political feasibility of program evaluation.  In general, we 
argue that the shift will increase the difficulty in conducting impact evaluation, because it will 
lead to larger sets of relevant outcomes, more diversity of sources of intervention co-funding and 
use of inputs whose value is difficult to establish, fewer options for evaluation study designs, 
increased difficulty in forecasting when and where exposure to the intervention and outcomes 
will occur, longer lag times between intervention start and impact on outcomes, larger numbers 
of mediating factors in the causal chain from intervention to outcome, and reduced motivation of 
political leaders and front-line staff to support impact evaluation.  Donors’ expressions of 
commitment to rigorous evaluation – and to the use of evaluation results in adjusting 
interventions – conflict with their actions shifting investments away from vertical HIV 
interventions to interventions benefitting the general health system.  Of course, such a conflict 
does not necessarily imply that donors are not credibly committed to rigorous evaluation.  The 
two shifts have plausibly occurred for independent reasons and may not have been considered 
jointly.  The vertical HIV interventions of the past were not well evaluated because the 
commitment to research proving intervention impact in different contexts was lacking.  As a 
result of the two conflicting shifts in priorities, we may yet again fail to learn about intervention 
impact, despite donors’ commitment to rigorous impact evaluation, because of the difficulty in 
evaluating impact of interventions affecting the general health system.  
15 
 This is not to say that rigorous evaluations of horizontal interventions will be impossible.  
Examples of rigorous evaluations of horizontal health systems interventions exist.
42 44 45  
However, it is likely that such evaluations will require substantially more resources than 
evaluations of vertical programs and that it will take longer before evaluations results will 
become available, implying that one of the purposes of evaluation – timely adjustments of 
interventions – will be harder to meet.  Delays in results on impact will be risky because 
interventions that have little impact, or cause harm, will continue for longer before corrective 
action can be taken. Our accounts of effects of the shift in intervention structure on our ability to 
evaluate the impact of interventions are based on a highly stylized distinction between vertical 
and horizontal interventions and are meant as ideal-type descriptions rather than as occurring 
necessarily in all comparisons of particular vertical and horizontal interventions.  In fact, it is not 
difficult to identify a few exceptions from many of the general comparisons. For instance, the 
provision of bus transport to improve patient access to care may be easier to evaluate than many 
vertical programs (such as vertical ART programs), because this particular horizontal 
intervention has few inputs and is likely to improve health outcomes relatively quickly. 
Policymakers and funders thus need to consider carefully the feasibility of impact evaluation of 
each particular intervention.  In addition, it is likely that new methods need to be developed and 
tested to allow timely, rigorous evaluation of horizontal interventions intended to benefit 
primarily HIV-infected populations.  Our article describes a general framework that can help 
guide these considerations and serve as a starting point for developing new methods. None of the 
factors we present represents a decisive argument against a change from vertical to horizontal 
interventions, but they do merit consideration in the choice of broad intervention strategy. 
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